Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: A case report

Journal of Medical Case Reports

Volumn 6, Issue , 2012, Pages

  Okuwaki, Yusuke ^a   Nakazawa, Takahide ^a   Hidaka, Hisashi ^a   Shibuya, Akitaka ^a   Koizumi, Wasaburo ^a  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Late onset response; Molecular targeted drug; Progressive disease; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; SORAFENIB; TS 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DOSE REDUCTION; ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; JAPANESE; LIVER CELL CARCINOMA; LOBECTOMY; LUNG METASTASIS; MALE; PORTAL VEIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN MANIFESTATION;

EID: 84856082759     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-6-38     Document Type: Article

References (14)

1. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
2. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, Tsuchihashi T, Saigenji K, AJR Am J Roentgenol 2007 188 480 488 10.2214/AJR.05.2079 17242258 (Pubitemid 46170753)
3. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, Ono K, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K, Oncology 2007 73 90 97 10.1159/000120996 18337620 (Pubitemid 351465606)
4. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, Kokubu S, Saigenji K, J Gastroenterol 2008 43 71 78 10.1007/s00535-007-2123-z 18297439 (Pubitemid 351324989)
5. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma. Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, Watanabe M, Shibuya A, Minamino T, Saigenji K, Am J Gastroenterol 2009 104 2747 2753 10.1038/ajg.2009.414 19603009
6. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Lopez PM, Villanueva A, Llovet JM, Aliment Pharmacol Ther 2006 23 1535 1547 10.1111/j.1365-2036.2006. 02932.x 16696801 (Pubitemid 43727460)
7. Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, SHARP Investigators Study Group, N Engl J Med 2008 359 378 390 10.1056/NEJMoa0708857 18650514
8. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z, Lancet Oncol 2009 10 25 34 10.1016/S1470-2045(08)70285-7 19095497
9. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, Matsuyama Y, Okazaki M, Okita K, Omata M, Saida Y, Takayama T, Yamaoka Y, Hepatol Res 2008 38 37 51 10.1111/j.1872-034X. 2007.00216.x 18039202 (Pubitemid 350182575)
10. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J, Eur J Cancer 2009 45 228 247 10.1016/j.ejca.2008.10.026 19097774
11. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Lencioni R, Llovet JM, Semin Liver Dis 2010 30 52 60 10.1055/s-0030-1247132 20175033
12. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg SN, Bhatt RS, PLoS One 2011 6 19144 10.1371/journal.pone. 0019144 21559452
13. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib-a report of two cases. Nakazawa T, Hidaka H, Shibuya A, Koizumi W, Case Rep Oncol 2010 3 298 303 10.1159/000319831 21347197
14. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H, BJU Int 2011 108 1813 1819 10.1111/j.1464-410X.2011. 10281.x 21481133